Immediate Impact

1 by Nobel laureates 1 from Science/Nature 62 standout
Sub-graph 1 of 23

Citing Papers

Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2–5 Years with Cystic Fibrosis and at Least One F508del Allele
2023 Standout
Cystic Fibrosis
2023 Standout
7 intermediate papers

Works of Guy‐André Loeuille being referenced

Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis
1998
Tolerance, pharmacokinetics and efficacy of once daily amikacin for treatment of Pseudomonas aeruginosa pulmonary exacerbations in cystic fibrosis patients
1996

Author Peers

Author Last Decade Papers Cites
Guy‐André Loeuille 126 46 21 65 56 17 252
Justin B. Usery 52 26 45 52 17 19 275
John Iazzetta 22 44 28 18 82 23 251
Ramesh Srinivasan 70 31 51 44 26 26 292
Bryan Lizza 35 4 9 100 30 25 291
van der Linden 47 13 9 39 63 14 284
Evren Şentürk 84 3 13 36 6 27 284
Gregor P.M. Mannes 219 4 13 48 18 10 297
Yehuda Baumoehl 46 4 2 47 9 16 288
Nicole Werner 30 14 27 54 21 12 194
Hafeez Abiola Afolabi 23 15 3 15 12 26 207

All Works

Loading papers...

Rankless by CCL
2026